Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24869931
Year: 2014
Citation:
  • Oncologist. 19(7):693-701, 2014 Jul.
Institution:
  • Washington Cancer Institute
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM
DOI:
Add to cart
2.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
  • Swain, Sandra M
PMID:
  • 34890214
Year: 2022
Citation:
  • Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department:
  • Associate Dean for Research Development
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
DOI:
Add to cart
Pages

Powered by Koha